Next Science Limited (NXSCF)

Market Cap	18.07M
Revenue (ttm)	22.82M
Net Income (ttm)	-10.59M
Shares Out	n/a
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,000
Average Volume	6,695
Open	0.0936
Previous Close	0.0550
Day's Range	0.0550 - 0.0936
52-Week Range	0.0320 - 0.2150
Beta	1.31
RSI	55.36
Earnings Date	Apr 22, 2025

About Next Science

Next Science Limited engages in the research, development, and commercialization of technologies that resolve the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand. It offers SURGX, an antimicrobial wound Gel; acne gel; oral rinse; BACTISURE wound lavage; BlastX, an antimicrobial wound gel that provides wound management by maintaining a moist wound environment, which is conducive to wound healing; and XPERIENCE for use in cleansing and removal of debris, i...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2012
• Country: Australia
• Stock Exchange: OTCMKTS
• Ticker Symbol: NXSCF

Financial Performance

In 2024, Next Science's revenue was $22.82 million, an increase of 2.87% compared to the previous year's $22.18 million. Losses were -$10.59 million, -34.94% less than in 2023.